JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

Search

Charles River Laboratories International Inc

Cerrado

SectorSanidad

169.88 1.41

Resumen

Variación precio

24h

Actual

Mínimo

166.98

Máximo

169.89

Métricas clave

By Trading Economics

Ingresos

-332M

-277M

Ventas

-11M

994M

Margen de beneficios

-27.816

Empleados

18,300

EBITDA

730K

198M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+17.62% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 may 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

1.2B

9.2B

Apertura anterior

168.47

Cierre anterior

169.88

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

Charles River Laboratories International Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

24 abr 2026, 19:19 UTC

Adquisiciones, fusiones, absorciones

Intertek Group Rejects EQT's Revised Offer

24 abr 2026, 23:37 UTC

Adquisiciones, fusiones, absorciones

Scoring the Cook Era -- Barrons.com

24 abr 2026, 20:51 UTC

Adquisiciones, fusiones, absorciones

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 abr 2026, 20:50 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Financial Services Roundup: Market Talk

24 abr 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

24 abr 2026, 20:39 UTC

Adquisiciones, fusiones, absorciones

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 abr 2026, 20:09 UTC

Ganancias

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24 abr 2026, 19:48 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24 abr 2026, 19:25 UTC

Adquisiciones, fusiones, absorciones

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 abr 2026, 19:25 UTC

Adquisiciones, fusiones, absorciones

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24 abr 2026, 19:22 UTC

Ganancias

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24 abr 2026, 19:06 UTC

Ganancias

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24 abr 2026, 19:05 UTC

Charlas de Mercado

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24 abr 2026, 18:30 UTC

Adquisiciones, fusiones, absorciones

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24 abr 2026, 18:28 UTC

Adquisiciones, fusiones, absorciones

Intertek Rejects Revised EQT Offer

24 abr 2026, 18:12 UTC

Charlas de Mercado

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24 abr 2026, 18:06 UTC

Charlas de Mercado

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24 abr 2026, 17:42 UTC

Ganancias

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24 abr 2026, 17:28 UTC

Ganancias

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

24 abr 2026, 17:28 UTC

Charlas de Mercado

Crypto Fear and Greed Index Slides Back to Neutral -- Market Talk

24 abr 2026, 17:12 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

24 abr 2026, 17:11 UTC

Charlas de Mercado

Apple Seen Gaining Market Share Despite Memory Crunch -- Market Talk

24 abr 2026, 17:09 UTC

Charlas de Mercado
Ganancias

Intel Seen With Stronger Long-Term Earnings Power -- Market Talk

24 abr 2026, 17:09 UTC

Adquisiciones, fusiones, absorciones

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 abr 2026, 17:06 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Correction to Advanced Micro Devices Stock Gets Upgraded to Buy. Why It's the Big Winner of Intel Earnings. -- Barrons.com

24 abr 2026, 16:51 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Two Big Loan Defaults Add to Pain in Private-Credit Funds -- WSJ

24 abr 2026, 16:20 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

24 abr 2026, 16:20 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Financial Services Roundup: Market Talk

24 abr 2026, 16:20 UTC

Charlas de Mercado
Ganancias

Auto & Transport Roundup: Market Talk

24 abr 2026, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Charles River Laboratories International Inc previsión

Precio Objetivo

By TipRanks

17.62% repunte

Estimación a 12 Meses

Media 197.3 USD  17.62%

Máximo 235 USD

Mínimo 160 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Charles River Laboratories International Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

11 ratings

7

Comprar

4

Mantener

0

Vender

Puntuación técnica

By Trading Central

117.16 / 144.77Soporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.